Legend Biotech (LEGN)
(Delayed Data from NSDQ)
$45.30 USD
+0.88 (1.98%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $45.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LEGN 45.30 +0.88(1.98%)
Will LEGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LEGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LEGN
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma
Why Legend Biotech (LEGN) Stock Might be a Great Pick
LEGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Company News for Mar 12, 2024
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
Other News for LEGN
Legend Biotech participates in a conference call with JPMorgan
Legend Biotech participates in a conference call with JPMorgan
NantHealth Welcomes Marc Harrison as Chief Legal Officer to Executive Team
Baron Health Care Fund Q1 2024 Shareholder Letter
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)